Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Avizafone→

Avizafone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
65617-86-9
Molecular formula
C22H27ClN4O3
Molecular weight
430.9 g/mol
Drug class
Benzodiazepine prodrugwater-soluble diazepam precursor and anticonvulsant
Mechanism of action
A water-soluble prodrug that is hydrolysed to diazepam. Diazepam enhances GABAA receptor-mediated inhibitory neurotransmission by positive allosteric modulation at the benzodiazepine site, producing anticonvulsant, anxiolytic, sedative and muscle-relaxant effects.
Indications / reported uses
  • Developed as an injectable or autoinjector prodrug of diazepam for emergency treatment of seizures, including seizure management in military nerve-agent medical countermeasure protocols. Product availability and current authorisation are limited.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=avizafone · https://pubmed.ncbi.nlm.nih.gov/?term=avizafone+diazepam+prodrug · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Avizafone Environmental Risk Assessment (ERA) (the Avizafone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.